Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1

被引：0
|
作者：
Carneiro, Ana
Yachnin, Jeffrey
Aljumaily, Raid
Abel, Edvard
Falchook, Gerald Steven
Ji, Yan
Borggren, Marie
Martensson, Linda
Gertsson, Susanne
Karlsson, Ingrid
Teige, Ingrid
Tehranchi, Ramin
Wallin, Johan Erik
Chisamore, Michael Jon
Frendeus, Bjorn
McAllister, Andres
机构：
[1] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Comprehens Canc Ctr, Lund, Sweden
[2] Karolinska Comprehens Canc Ctr, Stockholm, Sweden
[3] OU Hlth Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[6] Hlth Partners, St Paul, MN USA
[7] BioInvent, Lund, Sweden
[8] Merck & Co Inc, Rahway, NJ USA
[9] BioInvent Int, Lund, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012
    Bang, Yung-Jue
    Chung, Hyun-Choel
    Shankaran, Veena
    Geva, Ravit
    Catenacci, Daniel Virgil Thomas
    Gupta, Shilpa
    Eder, Joseph Paul
    Berger, Raanan
    Gonzalez, Edward J.
    Ray, Archana
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Pathiraja, Kumudu
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Koshiji, Minori
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
    Hussein, M.
    Percent, I.
    Arrowsmith, E.
    Arkenau, H-T.
    Chu, Q.
    Hansen, A. R.
    Erzen, D.
    Qiu, S.
    Lucarelli, A.
    Ulahannan, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S605 - S605
  • [43] Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
    Sanborn, Rachel E.
    Pishvaian, Michael J.
    Callahan, Margaret K.
    Weise, Amy
    Sikic, Branimir, I
    Rahma, Osama
    Cho, Daniel C.
    Rizvi, Naiyer A.
    Sznol, Mario
    Lutzky, Jose
    Bauman, Julie E.
    Bitting, Rhonda L.
    Starodub, Alexander
    Jimeno, Antonio
    Reardon, David A.
    Kaley, Thomas
    Iwamoto, Fabio
    Baehring, Joachim M.
    Subramaniam, Deepa S.
    Aragon-Ching, Jeanny B.
    Hawthorne, Thomas R.
    Rawls, Tracey
    Yellin, Michael
    Keler, Tibor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [44] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [46] Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
    Inoue, Takashi
    Narukawa, Mamoru
    CANCER CONTROL, 2022, 29
  • [47] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Moindrot, Nicolas
    Larois, Christelle
    Classe, Marion
    Sidhu, Sukhvinder
    CANCER RESEARCH, 2024, 84 (06)
  • [48] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Daphne Day
    John J. Park
    Jermaine Coward
    Ben Markman
    Charlotte Lemech
    James C. Kuo
    Amy Prawira
    Michael P. Brown
    Sarwan Bishnoi
    Dusan Kotasek
    R. Matthew Strother
    Rasha Cosman
    Rila Su
    Yiding Ma
    Zenglian Yue
    Hui-han Hu
    Rachel Wu
    Peiqi Li
    Archie N. Tse
    British Journal of Cancer, 2023, 129 : 1608 - 1618
  • [49] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Day, Daphne
    Park, John J.
    Coward, Jermaine
    Markman, Ben
    Lemech, Charlotte
    Kuo, James C.
    Prawira, Amy
    Brown, Michael P.
    Bishnoi, Sarwan
    Kotasek, Dusan
    Strother, R. Matthew
    Cosman, Rasha
    Su, Rila
    Ma, Yiding
    Yue, Zenglian
    Hu, Hui-han
    Wu, Rachel
    Li, Peiqi
    Tse, Archie N.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1608 - 1618
  • [50] Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takuya
    Hachiga, Kosuke
    Shichino, Shigeyuki
    Terashima, Yuya
    Toda, Etsuko
    Shand, Francis H. W.
    Kakimi, Kazuhiro
    Ito, Satoru
    Matsushima, Kouji
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) : 631 - 640
12345